DBD vs QLYS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DBD presents a stark dichotomy between explosive earnings growth and concerning sentiment indicators. With a Piotroski F-Score of 4/9, the company's financial health is categorized as stable but lacks strong momentum. While the stock currently trades at a premium to its Graham Number ($42.15) and Intrinsic Value ($74.93), the low forward P/E of 12.75 suggests the market is pricing in continued earnings acceleration. However, heavy insider liquidation and a bearish technical trend significantly offset the strong analyst 'strong_buy' consensus.
Qualys exhibits a dichotomy between strong fundamental health and severe market pessimism. The Piotroski F-Score of 4/9 indicates a stable financial condition, supported by an exceptionally low Debt/Equity ratio (0.09) and high gross margins (82.85%). While the stock is trading significantly below its growth-based intrinsic value ($160.48) and carries an attractive forward P/E of 10.42, this is offset by a bearish technical trend (0/100) and consistent insider selling. The company is a high-quality operator currently trapped in a valuation reset.
Compare Another Pair
Related Comparisons
DBD vs QLYS: Head-to-Head Comparison
This page compares Diebold Nixdorf, Incorporated (DBD) and Qualys, Inc. (QLYS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.